Chunying Shi

Stem-cell-capturing collagen scaffold promotes cardiac tissue regeneration

Stem cell based therapy is coming of age. Besides stem cell transplantation, it has been a goal to use native autologous stem cells for tissue regeneration. However, the recruitment of native autologous stem cells at the targeting site has not been sufficient which limits the clinical application of autologous stem cells. Biomaterials have been increasingly used in tissue repair. They not only serve as scaffolds for cell proliferation, differentiation, and also provide guidance for 3-D reestablishment. In this study, we have attempted to enrich autologous stem cells at the wound site through a stem-cell-capturing collagen scaffold by conjugating with a stem cell specific antibody. Sca-1 is a common surface marker of hematopoietic, cardiac and skeletal muscle stem cells. Due to the interaction of antibody and antigen, Sca-1 positive cells could be enriched to the functional collagen scaffold both in vitro and in vivo. When the functional collagen scaffold is transplanted into C57/BL6 mouse as a patch to repair a surgical heart defect, the regeneration of cardiomyocytes has been observed. Thus, the collagen scaffolds covalently conjugated with stem cell specific antibody could be an effective approach to promote tissue regeneration.

Regeneration of full-thickness abdominal wall defects in rats using collagen scaffolds loaded with collagen-binding basic fibroblast growth factor

Biomaterials are increasingly used in the repair of tissue defects. The aim of the present study was to evaluate a new composite biomaterial for reconstruction of a 2 × 2.5 cm full-thickness abdominal wall defect. In this study, the collagen membrane was activated with the engineered human basic fibroblast growth factor (bFGF). To enhance the binding of bFGF to collagen membranes, a specific peptide of collagen-binding domain (CBD) was fused to the N-terminal of bFGF. After implantation, little adhesion was caused in collagen/CBD-bFGF, collagen/NAT-bFGF and collagen/PBS groups. Moreover, collagen/CBD-bFGF group could effectively promote the vascularization at 30 d after surgery and significantly accelerate the integration of myofibers into the collagen material at 90 d after surgery compared to the other two groups. Due to the replacement of the myofibers in materials, the mechanical strength of implanted biomaterials in collagen/CBD-bFGF group was also greater than the other two groups at 90 d after surgery. Thus, the collagen/CBD-bFGF composite biomaterial was promising for the treatment of full-thickness abdominal wall defect.

Bladder Regeneration by Collagen Scaffolds With Collagen Binding Human Basic Fibroblast Growth Factor

PURPOSE Studies show that basic fibroblast growth factor can promote bladder regeneration. However, the lack of targeting delivery approaches limits its clinical application. We investigated a collagen based targeting system for bladder regeneration. A collagen binding domain was added to the native basic fibroblast growth factor N-terminal to allow it to bind to collagen. MATERIALS AND METHODS Sprague-Dawley rats underwent partial cystectomy. Collagen scaffolds loaded with collagen binding domain basic fibroblast growth factor, native basic fibroblast growth factor or phosphate buffered saline were grafted to the remaining host bladders, respectively. At days 30 and 90 reconstructed bladders were evaluated by histological analysis and urodynamics. RESULTS This targeting basic fibroblast growth factor delivery system induced satisfying bladder histological structures. It promoted more vascularization and smooth muscle cell ingrowth. Urodynamics revealed well accommodated bladder tissue with volume capacity and compliance. CONCLUSIONS Results show that the targeting delivery system consisting of collagen binding domain basic fibroblast growth factor and collagen membranes induced better bladder regeneration at the injury site. Thus, this targeting delivery system may be an effective strategy for bladder regeneration with potential clinical applications.

The osteogenic effect of bone morphogenetic protein-2 on the collagen scaffold conjugated with antibodies

Considerable research has been focused on the exploration of bone morphogenetic protein-2 (BMP(2)) delivery vehicles for achieving prolonged availability and maintaining efficient local concentration at the bone injury sites. In this study, heterobifunctional cross-linkers Sulfo-SMCC and cyclic thioimidate compound Trauts Reagent were used to conjugate monoclonal polyhistidine antibody on collagen scaffold demineralized bone matrix (DBM) to create specific binding between BMP(2) containing six histidines tag (His-BMP(2)) and DBM. According to the optimized cross-linking reagent concentration, more polyhistidine antibodies conjugated on DBM with 5mg/ml Trauts Reagent and 25ug/ml Sulfo-SMCC than physical adsorption. Monoclonal antibodies conjugated DBM (MAbs-DBM) could bind more His-BMP(2) than DBM and achieved controlled release in vitro. The alkaline phophatase (AP) activity of C2C12 cells on MAbs-DBM indicated that His-BMP(2) retained on MAbs-DBM preserved the function to induce osteogenic differentiation. His-BMP(2)/MAbs-DBM induced more ectopic bone formation (AP activity assay and histochemistry stain) than control group after subcutaneous implantation. The results demonstrated that antibody-collagen system could be useful for maintaining higher local therapy concentration of growth factors at the injury sites.

Urethral tissue regeneration using collagen scaffold modified with collagen binding VEGF in a beagle model

Extensive urethral defects have a serious impact on quality of life, and treatment is challenging. A shortage of material for reconstruction is a key limitation. Improving the properties of biomaterials and making them suitable for urethral reconstruction will be helpful. Previously, we constructed a fusion protein, collagen-binding VEGF (CBD-VEGF), which can bind to collagen scaffold, stimulate cell proliferation, and promote angiogenesis and tissue regeneration. We proposed that CBD-VEGF could improve the performance of collagen in reconstruction of extensive urethral defects. Our results showed that collagen scaffolds modified with CBD-VEGF could promote urethral tissue regeneration and improve the function of the neo-urethra in a beagle extensive urethral defect model. Thus, modifying biomaterials with bioactive factors provides an alternative strategy for the production of suitable biomaterials for urethral reconstruction.

Acceleration of wound healing in acute full-thickness skin wounds using a collagen-binding peptide with an affinity for MSCs

Mesenchymal stem cells (MSCs) have been accepted as a promising cell source in tissue repair and regeneration. However, the inability to enrich MSCs in target areas limits their wide application. As a result, it has been a major goal to induce MSCs to be abundantly and specifically recruited to the injury site. In this study, a peptide with a specific affinity for MSCs (E7 peptide) was immobilized to a collagen scaffold via a collagen-binding domain (CBD) to construct a functional collagen scaffold. In addition, the hypothesis that this method could recruit MSCs specifically was evaluated in a porcine model. In vivo investigations indicated that due to the immunore-action, the CBD-MSC-peptide collagen scaffold enhanced MSC adhesion and infiltration and promoted wound healing. At day 7 after surgery, we found more infiltrating cells and capillaries in the Collagen/CBD-E7 peptide group compared to the Scaffold group. At day 14, 21 and 28, a faster healing process was observed in the Collagen/CBD-E7 peptide group, with significant differences compared with the other groups (P < 0.05, P < 0.01). The results demonstrate the potential use of targeted therapy to rapidly heal skin wounds.

Modified VEGF targets the ischemic myocardium and promotes functional recovery after myocardial infarction.

Vascular endothelial growth factor (VEGF) promotes angiogenesis and improves cardiac function after myocardial infarction (MI). However, the non-targeted delivery of VEGF decreases its therapeutic efficacy due to an insufficient local concentration in the ischemic myocardium. In this study, we used a specific peptide to modify VEGF and determined that this modified VEGF (IMT-VEGF) localized to the ischemic myocardium through intravenous injection by interacting with cardiac troponin I (cTnI). When IMT-VEGF was used to mediate cardiac repair in a rat model of ischemia-reperfusion (I-R) injury, we observed a decreased scar size, enhanced angiogenesis and improved cardiac function. Moreover, an alternative treatment using the repeated administration of a low-dose IMT-VEGF also promoted angiogenesis and functional recovery. The therapeutic effects of IMT-VEGF were further confirmed in a pig model of MI as the result of the conserved properties of its interacting protein, cTnI. These results suggest a promising therapeutic strategy for MI based on the targeted delivery of IMT-VEGF.

The inhibition effects of insulin on BMP2-induced muscle heterotopic ossification

Bone morphogenetic proteins (BMPs) play an important role in regulating osteoblastic differentiation and bone formation. But the diffuse of BMPs into muscle tissues around bone injury sites often leads to heterotopic ossification, which has been regarded as one of major side-effects of BMP implementation in bone defect patients. It raises great demands for exploring effective methods that preventing BMP-induced heterotopic ossification while not interrupting the osteoinductive activity of BMPs for in situ bone defect repair. Here we found insulin, a positive regulator for bone regeneration, inhibited BMP2-induced muscle heterotopic ossification by suppressing the expression of bone transcription factor Osterix. By analyzing downstream molecules of insulin pathway, we found AKT/mTOR/GSK3 signaling was responsible for the inhibition of insulin on BMP2-induced ossification, and GSK3 inhibitor SB216763 attenuated BMP2-induced muscle heterotopic ossification. The data might shed light on developing effective clinical therapy for inhibiting muscle heterotopic ossification when BMPs were used bone defect repair.

MicroRNA-449c-5p inhibits osteogenic differentiation of human VICs through Smad4-mediated pathway

Calcific aortic valve disease (CAVD) is the most common heart valve disorder, yet its mechanism remains poorly understood. Valve interstitial cells (VICs) are the prevalent cells in aortic valve and their osteogenic differentiation may be responsible for calcific nodule formation in CAVD pathogenesis. Emerging evidence shows microRNA (miRNA, or miR) can function as important regulators of many pathological processes, including osteogenic differentiation. Here, we aimed to explore the function of miR-449c-5p in CAVD pathogenesis. In this study, we demonstrated the role of miR-449c-5p in VICs osteogenesis. MiRNA microarray assay and qRT-PCR results revealed miR-449c-5p was significantly down-regulated in calcified aortic valves compared with non-calcified valves. MiR-449c-5p overexpression inhibited VICs osteogenic differentiation in vitro, whereas down-regulation of miR-449c-5p enhanced the process. Target prediction analysis and dual-luciferase reporter assay confirmed Smad4 was a direct target of miR-449c-5p. Furthermore, knockdown of Smad4 inhibited VICs osteogenic differentiation, similar to the effect observed in up-regulation miR-449c-5p. In addition, animal experiments proved indirectly miR-449c-5p could alleviate aortic valve calcification. Our data suggested miR-449c-5p could function as a new inhibitory regulator of VICs osteogenic differentiation, which may act by targeting Smad4. MiR-449c-5p may be a potential therapeutic target for CAVD.

Differential effects of recombinant fusion proteins TAT-OCT4 and TAT-NANOG on adult human fibroblasts

OCT4 and NANOG are two important transcription factors for maintaining the pluripotency and selfrenewal abilities of embryonic stem (ES) cells. Meanwhile they play key roles in the induced pluripotent stem (iPS) cells. In this study, recombinant transcript factors TAT-NANOG and TAT-OCT4, which contained a fused powerful protein transduction domain (PTD) TAT from human immunodeficiency virus (HIV), were produced. Each fusion protein could be transported into human adult fibroblasts (HAF) successfully and activated the endogenous transcription of both nanog and oct4. Our study revealed the inter-regulation and autoregulation abilities of solo oct4 or nanog in the process of iPS cell reprogramming. Meanwhile the transduction of TAT-NANOG could accelerate the growth rate of HAF cells, and the key cell cycle regulator cdc25a was up-regulated. Thus cdc25a may be involved in the regulation of cell growth by NANOG. In addition, the TAT fusion protein technology provided a novel way to improve cell growth that is more controllable and safer.